2-hexyl-1-methyl-pyrrolidine | 3447-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-hexyl-1-methyl-pyrrolidine
• 英文别名: 2-Hexyl-1-methylpyrrolidine
• CAS: 3447-05-0
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: HKDFTJVSTOUWDV-UHFFFAOYSA-N

物化性质

• 沸点：
  93 °C(Press: 10 Torr)
• 密度：
  0.832±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Yamashita Hiroshi

  公开号：US20090264404A1

  公开（公告）日：2009-10-22

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，其化学式为（1）：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香族基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的谱，包括中枢神经系统障碍，无副作用且安全性高。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• HETEROCYCLIC COMPOUND
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1919907B1

  公开（公告）日：2011-02-23
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders
  申请人：Otsuka Pharmaceutical Co., Limited

  公开号：EP2284169B1

  公开（公告）日：2012-03-14
• SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP3519393B1

  公开（公告）日：2022-05-18